Company intelligence / Profile preview
Collaborations Pharmaceuticals, Inc.
- Ownership
- Private
- Employees
- ~14
- Development stage
- Other
Overview
Collaborations Pharmaceuticals has advanced multiple programs to preclinical and IND-enabling stages, particularly in rare diseases such as Batten disease. Their AI-driven approach has led to promising candidates for several rare and neglected diseases, with recent grants supporting late-stage development of an enzyme replacement therapy for Batten disease[10][6]. No clinical trial results or approved drugs have been reported as of May 2025.
- Therapeutic areas
- OncologyRare DiseasesPsychiatryNeurologyInfectious Diseases
- Modalities
- Small moleculesEnzyme replacement therapiesAntibody drug conjugates (ADC)
- Industry
- Biotech
Drug pipeline
11 assets10 more assets in the full pipeline.
Partnerships
Beyond the preview
Go deeper on Collaborations Pharmaceuticals, Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Collaborations Pharmaceuticals, Inc..